Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.
Fiche publication
Date publication
janvier 2015
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
About F, Oudot-Mellakh T, Niay J, Rabiéga P, Pedergnana V, Duffy D, Sultanik P, Cagnot C, Carrat F, Marcellin P, Zoulim F, Larrey D, Hézode C, Fontaine H, Bronowicki JP, Pol S, Albert ML, Theodorou I, Cobat A, Abel L,
Lien Pubmed
Résumé
Human genetic factors influence the outcome of pegylated interferon and ribavirin hepatitis C therapy. We explored the role of IL28B, APOH and ITPA SNPs on the outcomes of triple therapy including telaprevir or boceprevir in patients with compensated cirrhosis chronically infected with HCV-1.
Mots clés
Anemia, complications, Drug Therapy, Combination, Hemoglobins, metabolism, Hepacivirus, physiology, Hepatitis C, Chronic, complications, Humans, Interleukins, genetics, Liver Cirrhosis, complications, Oligopeptides, adverse effects, Polymorphism, Single Nucleotide, genetics, Proline, adverse effects, Pyrophosphatases, genetics, Treatment Outcome, beta 2-Glycoprotein I, genetics
Référence
PLoS ONE. 2015 ;10(12):e0145105